We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Homocysteine Affects Outcome of Cardiac Transplants

By HospiMedica staff writers
Posted on 10 Nov 2000
In an animal study, high levels of homocysteine were found to increase the risk of chronic rejection in heart transplant patients. More...
The study suggests that heart transplant patients may be able to reduce this risk by changing their diet to include vitamins B12, B6, or folate in advance of surgery to keep homocysteine levels low. The findings were reported at the annual Clinical Congress of the American College of Surgeons in Chicago (IL, USA).

In the study, one group of animals were fed a diet high in methionine and low in folate, while control animals received a normal diet. After two weeks, the experimental animals developed hyperhomocysteinemia with levels about 20 times higher than controls. In these animals, cardiac transplant grafts survived only 59 days, while grafts in animals receiving a normal diet survived an average of 107 days. The time to onset of rejection was also accelerated in the animals on a high homocysteine diet, averaging 42 days in test animals and 66 days in controls.

The researchers focused on studying homocysteine because of its known relationship to the development of atherosclerosis. In the study, high homocysteine levels are assumed to have contributed to the atherosclerotic process, which decreased the blood supply to cardiac grafts and caused the grafts to fail. The research was conducted by Dr. Susan L. Orloff, of the Oregon Health Sciences University (Portland, USA), and colleagues.

"This animal study shows that we can cause high levels of homocysteine and demonstrate a cause-and-effect relationship with vascular disease in cardiac grafts,” explained Dr. Orloff.

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.